Two new compound classes (isoform selective and non-selective) of Rho kinase (ROCK) inhibitors have been discovered for use as anticancer drugs. Lead candidates of both classes have been evaluated in animal models. Potential uses in cardiovascular indications are also possible.
Two novel compound classes (Class A and Class B) of Rho kinase (ROCK) inhibitors have been discovered for use as anticancer drugs. Potential uses in cardiovascular indications are also possible. The Rho kinase isoforms, ROCK1 and ROCK2, were initially discovered as downstream targets of the small GTP-binding protein Rho. Because ROCKs mediate various important cellular functions such as cell shape, motility, secretion, proliferation, and gene expression, this pathway plays a pivotal role in the regulation of numerous cellular functions associated with malignant transformation and metastasis.
These two classes encompass compositions and methods for blocking cancer cell growth or proliferation and/or inducing cancer cell death – a central event in the process of metastasis.